Immunic Therapeutics

Name: Immunic Therapeutics
Address: 1200 Avenue of the Americas, Suite 200, New York, NY, NY10036, US
Telephone: +4989208047700

Home
United States
New York, NY
Immunic Therapeutics

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of select

08/11/2026

Today, we reported our second quarter 2026 and provided a . Highlights include:

📣 Leadership team expanded with key executive appointments, including CEO, CMO and Chair of the Board, to support clinical development, as well as NDA and commercial readiness

🚀 Pivotal phase 3 trials of calcium ( ) in relapsing ( , ) on track, with top-line data expected by end of 2026

📈 Continued preparations for phase 3 trial of vidofludimus calcium in progressive MS ( ), with initiation planned later this year

👉 Get all the details here: https://bit.ly/4wpKPm2

08/10/2026

🔬 advances through collaboration.

We are proud to share a new publication led by our Vice President Clinical Development & Medical Lead MS, Matej Ondrus, MD, together with Dr. Robert Fox of Cleveland Clinic and colleagues across . The review explores why next-generation ( ) therapies should address both and long-term disability progression, and discusses the scientific rationale and clinical development status of our lead asset in phase 3 clinical testing, calcium.

Congratulations to Matej and all co-authors on this great achievement.

📖 Read the full publication here: https://6z11edl.s.gy/e0zhW6

08/06/2026

🎙️ is driven by both and . What could this mean for future treatment approaches?

On the NR Times podcast, 's President & COO, Jason Tardio, discusses our approach to multiple sclerosis ( ), shares insights from our clinical programs, and highlights upcoming milestones that could help shape the future of MS treatment.

Listen to the episode here: https://bit.ly/4btUwbn

08/05/2026

📍 Meet the Team at the Autoimmune Neurology Conference in from August 7-8! 🧠

🤝 We are looking forward to connecting with members of the community, sharing insights, discussing emerging research, and exploring ways to improve outcomes for people living with neurological disorders such as ( ).

If you attend, let's connect!

American Academy of Neurology (AAN)

08/03/2026

🏆 We are proud to see our Co-Founder and Director, Dr. Daniel Vitt, recognized in The Medicine Maker Power List 2026 in the Small Molecules category.

Since co-founding back in 2016, Daniel has helped guide the company from an early-stage venture to a late-stage, pre-commercial clinical company, helping shape the scientific strategy behind our lead investigational asset, calcium.

🎉 Congratulations, Daniel, on this recognition and thank you for your vision, scientific leadership, and continued contributions to . 👏

🔗 Read more: https://bit.ly/4vISDPu

07/31/2026

🌈 During ♿, we recognize the importance of and full participation in the everyday life of everybody regardless of their limitations. Inclusion means creating opportunities for people to participate fully in family life, social activities, work, and the everyday experiences that matter to them.

🧠 For people living with ( ), maintaining neurological function can play an important role in supporting independence and participation throughout life. This understanding continues to shape research efforts aimed at addressing the long-term impact of the disease.

At , we are committed to advancing research in MS, including our lead investigational candidate calcium. Medicine moves forward by listening to people living with disease, understanding what matters most to them, and pursuing approaches that may help make a meaningful difference. 🧡

07/29/2026

🤝 Meet the Medical Affairs team at the 2026 Texas Neurological Society ( ) Summer Conference in , July 31 - August 1.

We look forward to engaging with healthcare professionals, exchanging perspectives on the management of neurological diseases, and discussing the latest developments in ( ) research.

If you are attending, let's connect.

07/27/2026

🔬 A new study published in Science Translational Medicine strengthens the evidence linking virus ( ) and ( ), identifying enhanced immune responses to specific EBV antigens in people living with MS. The findings provide important insight into how EBV may contribute to disease processes in MS.

🧠 As our understanding of MS biology continues to evolve, so does the opportunity to develop new innovative therapeutic approaches. 's investigational drug candidate calcium is designed to modulate inflammatory immune responses while potentially supporting neuroprotective pathways and has also shown antiviral activity in preclinical studies, including against EBV.

👉 Get all the details on the new research here: https://bit.ly/3TK5q6F

07/24/2026

🛫 Three cities. Two weeks. One leadership team.

Following meetings in last week and in and this week, CEO Erik Lundgren, President & COO Jason Tardio and CMO Dr. Mike Panzara wrapped up a very successful meeting marathon at the LifeSci Capital SF Forum.

🤝 Thank you to the Capital team for bringing together and leaders for an event of focused discussions and exchange.

🏠 Now, after a productive stretch on the road, the team is heading home with valuable insights and many conversations to build on.

07/22/2026

🧠 Time matters when it comes to brain health.

For many people living with neurological diseases such as ( ), the journey to an accurate diagnosis can take years. Delayed diagnosis may mean missed opportunities for timely and .

On , we join the World Federation of Neurology - WFN's call for better access to neurological care, earlier diagnosis, and timely intervention worldwide. Because protecting health starts with helping people reach the right expertise at the right time.

At , this mission resonates strongly with our focus on advancing research in MS, where early recognition and treatment may play an important role for improving long-term outcomes.

Address

1200 Avenue Of The Americas, Suite 200
New York, NY
NY10036

Telephone

+4989208047700

Website

https://www.imux.com/

Alerts

Be the first to know and let us send you an email when Immunic Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Want your business to be the top-listed Engineering Company in New York?